LIR Life Sciences Corp.
SKNY
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 1,577.98% | 357.33% | 182.53% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 1,588.08% | 360.59% | 206.93% | ||
| Operating Income | -1,588.08% | -360.59% | -206.93% | ||
| Income Before Tax | -1,840.75% | -359.93% | -207.23% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -1,840.75% | -359.93% | -207.23% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -1,840.75% | -359.93% | -207.23% | ||
| EBIT | -1,588.08% | -360.59% | -206.93% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -138.02% | 98.81% | 99.19% | ||
| Normalized Basic EPS | -143.71% | 98.80% | 99.18% | ||
| EPS Diluted | -138.02% | 98.81% | 99.19% | ||
| Normalized Diluted EPS | -143.71% | 98.80% | 99.18% | ||
| Average Basic Shares Outstanding | 714.97% | 38,689.00% | 37,900.00% | ||
| Average Diluted Shares Outstanding | 714.97% | 38,689.00% | 37,900.00% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||